{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T21:58:25Z","timestamp":1769464705416,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clinthera.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T23:29:38Z","timestamp":1646609378000},"page":"624-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Target Attainment of 3-Hour Extended Infusion of Meropenem in Patients With Septic Burns"],"prefix":"10.1016","volume":"44","author":[{"given":"Claudia Garcia","family":"Messiano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-3717","authenticated-orcid":false,"given":"Ronaldo","family":"Morales Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Otofuji","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elson Mendes da","family":"Silva Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David de Souza","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Regina Cavani Jorge","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.02.007_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41038-017-0089-5","article-title":"Sepsis in the burn patient: a different problem than sepsis in the general population","volume":"5","author":"Greenhalgh","year":"2017","journal-title":"Burns Trauma"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/sur.2020.375","article-title":"Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Burn Patients","volume":"22","author":"Pruskowski","year":"2021","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0003","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FTD.0b013e31824981a6","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in burns patients\u2013a one-year prospective study","volume":"34","author":"Patel","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0004","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/jac\/dkq317","article-title":"Population pharmacokinetics of meropenem in burn patients","volume":"65","author":"Doh","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics\u2013pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0008","first-page":"4","article-title":"Pharmacokinetic-pharmacodynamic correlation for meropenem applied to a burn child using a bioanalytical liquid chromatographic method","volume":"3","author":"Santos","year":"2011","journal-title":"Braz J Pharma Sci"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0009","unstructured":"MERREM intravenous injection. Package insert. AstraZeneca Pharmaceuticals LP (per FDA), 1996. Accessed January 25, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050706s037lbl.pdf"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dkg378","article-title":"Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection","volume":"52","author":"Jaruratanasirikul","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0011","unstructured":"Clinical & Laboratory Standards Institute: CLSI Guidelines. Clinical & Laboratory Standards Institute. Accessed July 19, 2021. https:\/\/clsi.org\/."},{"key":"10.1016\/j.clinthera.2022.02.007_bib0012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/CMR.19.2.403-434.2006","article-title":"Burn Wound Infections","volume":"19","author":"Church","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does Beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? a systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0034-1398490","article-title":"Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development","volume":"36","author":"Abdul-Aziz","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.burns.2009.10.012","article-title":"Incidence and bacteriology of burn infections at a military burn center","volume":"36","author":"Keen","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jgar.2019.06.011","article-title":"Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: are we getting close to the right treatment?","volume":"20","author":"Corcione","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0017","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.burns.2011.01.019","article-title":"Common pathogens in burn wound and changes in their drug sensitivity","volume":"37","author":"Rezaei","year":"2011","journal-title":"Burns"},{"key":"10.1016\/j.clinthera.2022.02.007_bib0018","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","article-title":"Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations","volume":"70","author":"Ramon-Lopez","year":"2015","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:25Z","timestamp":1758963445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0149291822000777"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.02.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Target Attainment of 3-Hour Extended Infusion of Meropenem in Patients With Septic Burns","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}